Role of agmatine in neurodegenerative diseases and epilepsy

Frontiers in Bioscience - Elite

Volumn 6 E, Issue 2, 2014, Pages 341-359

  Moretti, Morgana ^a   Matheus, Filipe C ^a   De Oliveira, Paulo A ^a   Neis, Vivian B ^a   Ben, Juliana ^a   Walz, Roger ^a   Rodrigues, Ana Lucia S ^a   Prediger, Rui Daniel ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Agmatine; Depression; Epilepsy; Neurodegenerative disease; Neuroprotection; Review

Indexed keywords

AGMATINE; FLUOXETINE; IDAZOXAN;

ALZHEIMER DISEASE; ANTICONVULSANT THERAPY; ANTIDEPRESSANT ACTIVITY; DEPRESSION; EPILEPSY; HUMAN; LEARNING; LONG TERM MEMORY; MEMORY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; TRAUMATIC BRAIN INJURY;

AGMATINE; ANTIDEPRESSIVE AGENTS; BRAIN INJURIES; CENTRAL NERVOUS SYSTEM; EPILEPSY; HUMANS; LEARNING; MEMORY; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84904515228     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e710     Document Type: Review

References (153)

1. C. W. Tabor and H. Tabor: Polyamines. Annu Rev Biochem, 53, 749-90 (1984)
2. E. Galea, S. Regunathan, V. Eliopoulos, D. L. Feinstein and D. J. Reis: Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J, 316 (Pt 1), 247-9 (1996)
3. S. Regunathan and J. E. Piletz: Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann N Y Acad Sci, 1009, 20-9 (2003)
4. M. Sastre, S. Regunathan, E. Galea and D. J. Reis: Agmatinase activity in rat brain: a metabolic pathway for the degradation of agmatine. J Neurochem, 67(4), 1761-5 (1996)
5. D. J. Reis and S. Regunathan: Agmatine: An Endogenous Ligand at Imidazoline Receptors Is a Novel Neurotransmittera. Ann N Y Acad Sci, 881(1), 65-80 (1999)
6. G. Li, S. Regunathan, C. J. Barrow, J. Eshraghi, R. Cooper and D. J. Reis: Agmatine: an endogenous clonidine-displacing substance in the brain. Science, 263(5149), 966-9 (1994)
7. G. E. N. Li, S. Regunathan and D. J. Reis: Agmatine Is Synthesized by a Mitochondrial Arginine Decarboxylase in Rat Brain. Ann N Y Acad Sci, 763(1), 325-329 (1995)
8. W. Raasch, S. Regunathan, G. Li and D. J. Reis: Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sciences, 56(26), 2319-2330 (1995)
9. K. Otake, D. A. Ruggiero, S. Regunathan, H. Wang, T. A. Milner and D. J. Reis: Regional localization of agmatine in the rat brain: an immunocytochemical study. Brain Res, 787(1), 1-14 (1998)
10. D. J. Reis, X.-C. Yang and T. A. Milner: Agmatine containing axon terminals in rat hippocampus form synapses on pyramidal cells. Neuroscience Letters, 250(3), 185-188 (1998)
11. S. Regunathan, D. L. Feinstein, W. Raasch and D. J. Reis: Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. Neuroreport, 6(14), 1897-900 (1995)
12. D. J. Reis and S. Regunathan: Agmatine: a novel neurotransmitter? Adv Pharmacol, 42, 645-9 (1998)
13. Y. Feng, A. E. Halaris and J. E. Piletz: Determination of agmatine in brain and plasma using high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Biomedical Sciences and Applications, 691(2), 277-286 (1997)
14. A. Halaris and J. Plietz: Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs, 21(11), 885-900 (2007)
15. Y. Feng, J. E. Piletz and M. H. Leblanc: Agmatine suppresses nitric oxide production and attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res, 52(4), 606-11 (2002)
16. G. M. Gilad, K. Salame, J. M. Rabey and V. H. Gilad: Agmatine Treatment Is Neuroprotective in Rodent Brain Injury Models. Life Sciences, 58(2), Pl41-Pl46 (1995)
17. C. A. Fairbanks, K. L. Schreiber, K. L. Brewer, C. G. Yu, L. S. Stone, K. F. Kitto, H. O. Nguyen, B. M. Grocholski, D. W. Shoeman, L. J. Kehl, S. Regunathan, D. J. Reis, R. P. Yezierski and G. L. Wilcox: Agmatine reverses pain induced by inflammation, neuropathy, and spinal cord injury. Proc Natl Acad Sci U S A, 97(19), 10584-9 (2000)
18. A. R. Santos, V. M. Gadotti, G. L. Oliveira, D. Tibola, A. F. Paszcuk, A. Neto, H. M. Spindola, M. M. Souza, A. L. Rodrigues and J. B. Calixto: Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology, 48(7), 1021-34 (2005)
19. Y. Kolesnikov, S. Jain and G. W. Pasternak: Modulation of opioid analgesia by agmatine. Eur J Pharmacol, 296(1), 17-22 (1996)
20. I. T. Uzbay, O. Yesilyurt, T. Celik, H. Ergun and A. Isimer: Effects of agmatine on ethanol withdrawal syndrome in rats. Behav Brain Res, 107(1-2), 153-9 (2000)
21. A. K. Bence, D. R. Worthen, J. P. Stables and P. A. Crooks: An in vivo evaluation of the antiseizure activity and acute neurotoxicity of agmatine. Pharmacol Biochem Behav, 74(3), 771-5 (2003)
22. R. B. Su, X. L. Wei, J. Q. Zheng, Y. Liu, X. Q. Lu and J. Li: Anticonvulsive effect of agmatine in mice. Pharmacol Biochem Behav, 77(2), 345-9 (2004)
23. Y. F. Li, Z. H. Gong, J. B. Cao, H. L. Wang, Z. P. Luo and J. Li: Antidepressant-like effect of agmatine and its possible mechanism. Eur J Pharmacol, 469(1-3), 81-8 (2003)
24. A. D. Zomkowski, L. Hammes, J. Lin, J. B. Calixto, A. R. Santos and A. L. Rodrigues: Agmatine produces antidepressant-like effects in two models of depression in mice. Neuroreport, 13(4), 387-91 (2002)
25. Z. H. Gong, Y. F. Li, N. Zhao, H. J. Yang, R. B. Su, Z. P. Luo and J. Li: Anxiolytic effect of agmatine in rats and mice. Eur J Pharmacol, 550(1-3), 112-6 (2006)
26. N. S. Arteni, D. Lavinsky, A. L. Rodrigues, V. B. Frison and C. A. Netto: Agmatine facilitates memory of an inhibitory avoidance task in adult rats. Neurobiol Learn Mem, 78(2), 465-9 (2002)
27. G. M. Gilad, V. H. Gilad, J. P. Finberg and J. M. Rabey: Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem Res, 30(6-7), 713-9 (2005)
28. F. C. Matheus, A. S. Aguiar, Jr., A. A. Castro, J. G. Villarinho, J. Ferreira, C. P. Figueiredo, R. Walz, A. R. Santos, C. I. Tasca and R. D. Prediger: Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behav Brain Res, 235(2), 263-72 (2012)
29. R. H. Loring: Agmatine Acts as an Antagonist of Neuronal Nicotinic Receptors. Br J Pharmacol, 99(1), 207-211 (1990)
30. X. C. Yang and D. J. Reis: Agmatine selectively blocks the N-methyl-D-aspartate subclass of glutamate receptor channels in rat hippocampal neurons. J Pharmacol Exp Ther, 288(2), 544-9 (1999)
31. Y. Gu, X. Fan, C. Zhang, X. Yang, Y. X. Bao and H. P. Liang: (The protective effects of agmatine in zymosan induced acute lung injury in mice). Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, 23(11), 665-8 (2011)
32. J. Satriano, D. Schwartz, S. Ishizuka, M. J. Lortie, S. C. Thomson, F. Gabbai, C. J. Kelly and R. C. Blantz: Suppression of inducible nitric oxide generation by agmatine aldehyde: Beneficial effects in sepsis. Journal of Cellular Physiology, 188(3), 313-320 (2001)
33. M. A. Arndt, V. Battaglia, E. Parisi, M. J. Lortie, M. Isome, C. Baskerville, D. P. Pizzo, R. Ientile, S. Colombatto, A. Toninello and J. Satriano: The arginine metabolite agmatine protects mitochondrial function and confers resistance to cellular apoptosis. Am J Physiol Cell Physiol, 296(6), C1411-9 (2009)
34. V. Battaglia, S. Grancara, J. Satriano, S. Saccoccio, E. Agostinelli and A. Toninello: Agmatine prevents the Ca(2+)-dependent induction of permeability transition in rat brain mitochondria. Amino Acids, 38(2), 431-7 (2010)
35. Y. F. Li, H. X. Chen, Y. Liu, Y. Z. Zhang, Y. Q. Liu and J. Li: Agmatine increases proliferation of cultured hippocampal progenitor cells and hippocampal neurogenesis in chronically stressed mice. Acta Pharmacol Sin, 27(11), 1395-400 (2006)
36. M. Y. Zhu, W. P. Wang, Z. W. Cai, S. Regunathan and G. Ordway: Exogenous agmatine has neuroprotective effects against restraint-induced structural changes in the rat brain. Eur J Neurosci, 27(6), 1320-32 (2008)
37. F. Aricioglu and H. Altunbas: Is agmatine an endogenous anxiolytic/antidepressant agent? Ann N Y Acad Sci, 1009, 136-40 (2003)
38. A. D. Zomkowski, A. R. Santos and A. L. Rodrigues: Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry, 30(8), 1419-25 (2006)
39. M. P. Zeidan, A. D. Zomkowski, A. O. Rosa, A. L. Rodrigues and N. H. Gabilan: Evidence for imidazoline receptors involvement in the agmatine antidepressant-like effect in the forced swimming test. Eur J Pharmacol, 565(1-3), 125-31 (2007)
40. S. Maeng, C. A. Zarate, Jr., J. Du, R. J. Schloesser, J. McCammon, G. Chen and H. K. Manji: Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry, 63(4), 349-52 (2008)
41. B. Szewczyk, E. Poleszak, M. Sowa-Kucma, A. Wrobel, S. Slotwinski, J. Listos, P. Wlaz, A. Cichy, A. Siwek, M. Dybala, K. Golembiowska, A. Pilc and G. Nowak: The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids, 39(1), 205-17 (2010)
42. M. Moretti, A. E. Freitas, J. Budni, S. C. Fernandes, O. Balen Gde and A. L. Rodrigues: Involvement of nitric oxide-cGMP pathway in the antidepressant-like effect of ascorbic acid in the tail suspension test. Behav Brain Res, 225(1), 328-33 (2011)
43. W. Raasch, U. Schafer, J. Chun and P. Dominiak: Biological significance of agmatine, an endogenous ligand at imidazoline binding sites. Br J Pharmacol, 133(6), 755-80 (2001)
44. D. J. Reis and S. Regunathan: Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci, 21(5), 187-93 (2000)
45. A. Dias Elpo Zomkowski, A. Oscar Rosa, J. Lin, A. R. Santos, J. B. Calixto and A. Lucia Severo Rodrigues: Evidence for serotonin receptor subtypes involvement in agmatine antidepressant like-effect in the mouse forced swimming test. Brain Res, 1023(2), 253-63 (2004)
46. B. G. Taksande, N. R. Kotagale, S. J. Tripathi, R. R. Ugale and C. T. Chopde: Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology, 57(4), 415-24 (2009)
47. M. Krass, G. Wegener, E. Vasar and V. Volke: Antidepressant-like effect of agmatine is not mediated by serotonin. Behav Brain Res, 188(2), 324-8 (2008)
48. A. D. Zomkowski, A. R. Santos and A. L. Rodrigues: Evidence for the involvement of the opioid system in the agmatine antidepressant-like effect in the forced swimming test. Neurosci Lett, 381(3), 279-83 (2005)
49. J. Budni, V. M. Gadotti, M. P. Kaster, A. R. Santos and A. L. Rodrigues: Role of different types of potassium channels in the antidepressant-like effect of agmatine in the mouse forced swimming test. Eur J Pharmacol, 575(1-3), 87-93 (2007)
50. M. Y. Zhu, W. P. Wang, J. Huang, Y. Z. Feng, S. Regunathan and G. Bissette: Repeated immobilization stress alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. Neurochem Int, 53(6-8), 346-54 (2008)
51. M. Y. Zhu, W. P. Wang, J. Huang and S. Regunathan: Chronic treatment with glucocorticoids alters rat hippocampal and prefrontal cortical morphology in parallel with endogenous agmatine and arginine decarboxylase levels. J Neurochem, 103(5), 1811-20 (2007)
52. B. G. Taksande, D. S. Faldu, M. P. Dixit, J. N. Sakaria, M. M. Aglawe, M. J. Umekar and N. R. Kotagale: Agmatine attenuates chronic unpredictable mild stress induced behavioral alteration in mice. Eur J Pharmacol, 720(1-3), 115-20 (2013)
53. A. Halaris, H. Zhu, Y. Feng and J. E. Piletz: Plasma agmatine and platelet imidazoline receptors in depression. Ann N Y Acad Sci, 881, 445-51 (1999)
54. B. Shopsin: The clinical antidepressant effect of exogenous agmatine is not reversed by parachlorophenylalanine: a pilot study. Acta Neuropsychiatrica, 25(02), 113-118 (2013)
55. G. M. Gilad, V. H. Gilad, M. F. Casanova and R. A. Casero, Jr.: Polyamines and their metabolizing enzymes in human frontal cortex and hippocampus: preliminary measurements in affective disorders. Biol Psychiatry, 38(4), 227-34 (1995)
56. S. Genedani, S. Saltini, A. Benelli, M. Filaferro and A. Bertolini: Influence of SAMe on the modifications of brain polyamine levels in an animal model of depression. Neuroreport, 12(18), 3939-42 (2001)
57. L. M. Fiori and G. Turecki: Implication of the polyamine system in mental disorders. J Psychiatry Neurosci, 33(2), 102-10 (2008)
58. E. R. Kandel: The molecular biology of memory storage: a dialogue between genes and synapses. Science, 294(5544), 1030-8 (2001)
59. B. Milner, L. R. Squire and E. R. Kandel: Cognitive neuroscience and the study of memory. Neuron, 20(3), 445-68 (1998)
60. B. E. McKay, W. E. Lado, L. J. Martin, M. A. Galic and N. M. Fournier: Learning and memory in agmatine-treated rats. Pharmacol Biochem Behav, 72(3), 551-7 (2002)
61. P. Liu, N. D. Collie, S. Chary, Y. Jing and H. Zhang: Spatial learning results in elevated agmatine levels in the rat brain. Hippocampus, 18(11), 1094-8 (2008)
62. B. Leitch, O. Shevtsova, K. Reusch, D. H. Bergin and P. Liu: Spatial learning-induced increase in agmatine levels at hippocampal CA1 synapses. Synapse, 65(2), 146-53 (2011)
63. S. Seo, P. Liu and B. Leitch: Spatial learning-induced accumulation of agmatine and glutamate at hippocampal CA1 synaptic terminals. Neuroscience, 192, 28-36 (2011)
64. M. Rushaidhi, Y. Jing, H. Zhang and P. Liu: Participation of hippocampal agmatine in spatial learning: an in vivo microdialysis study. Neuropharmacology, 65, 200-5 (2013)
65. P. Liu and D. H. Bergin: Differential effects of i.c.v. microinfusion of agmatine on spatial working and reference memory in the rat. Neuroscience, 159(3), 951-61 (2009)
66. P. Liu and N. D. Collie: Behavioral effects of agmatine in naive rats are task- and delay-dependent. Neuroscience, 163(1), 82-96 (2009)
67. M. Rushaidhi, N. D. Collie, H. Zhang and P. Liu: Agmatine selectively improves behavioural function in aged male Sprague-Dawley rats. Neuroscience, 218, 206-15 (2012)
68. M. Rushaidhi, H. Zhang and P. Liu: Effects of prolonged agmatine treatment in aged male Sprague-Dawley rats. Neuroscience, 234, 116-24 (2013)
69. P. Liu, Y. Jing, N. D. Collie, S. Chary and H. Zhang: Memory-related changes in L-citrulline and agmatine in the rat brain. Hippocampus, 19(7), 597-602 (2009)
70. W. Lu, H. J. Dong, Z. H. Gong, R. B. Su and J. Li: Agmatine inhibits morphine-induced memory impairment in the mouse step-down inhibitory avoidance task. Pharmacol Biochem Behav, 97(2), 256-61 (2010)
71. W. Lu, H. J. Dong, G. H. Bi, Y. Q. Zhao, Z. Yang, R. B. Su and J. Li: Effect of agmatine on long-term potentiation in morphine-treated rats. Pharmacol Biochem Behav, 96(2), 125-9 (2010)
72. X. F. Wang, N. Wu, R. B. Su, X. Q. Lu, Y. Liu and J. Li: Agmatine modulates neuroadaptations of glutamate transmission in the nucleus accumbens of repeated morphine-treated rats. Eur J Pharmacol, 650(1), 200-5 (2011)
73. M. A. Erickson, K. Dohi and W. A. Banks: Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation, 19(2), 121-30 (2012)
74. A. Zarifkar, S. Choopani, R. Ghasemi, N. Naghdi, A. H. Maghsoudi, N. Maghsoudi, K. Rastegar and M. Moosavi: Agmatine prevents LPS-induced spatial memory impairment and hippocampal apoptosis. Eur J Pharmacol, 634(1-3), 84-8 (2010)
75. T. Utkan, S. S. Gocmez, S. Regunathan and F. Aricioglu: Agmatine, a metabolite of L-arginine, reverses scopolamine-induced learning and memory impairment in rats. Pharmacol Biochem Behav, 102(4), 578-84 (2012)
76. L. T. Knox, Y. Jing, M. S. Fleete, N. D. Collie, H. Zhang and P. Liu: Scopolamine impairs behavioural function and arginine metabolism in the rat dentate gyrus. Neuropharmacology, 61(8), 1452-62 (2011)
77. M. Moosavi, G. Y. Khales, L. Abbasi, A. Zarifkar and K. Rastegar: Agmatine protects against scopolamine-induced water maze performance impairment and hippocampal ERK and Akt inactivation. Neuropharmacology, 62(5-6), 2018-23 (2012)
78. P. Bhutada, Y. Mundhada, V. Humane, A. Rahigude, P. Deshmukh, S. Latad and K. Jain: Agmatine, an endogenous ligand of imidazoline receptor protects against memory impairment and biochemical alterations in streptozotocin-induced diabetic rats. Prog Neuropsychopharmacol Biol Psychiatry, 37(1), 96-105 (2012)
79. G. M. Gilad and V. H. Gilad: Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci Lett, 296(2-3), 97-100 (2000)
80. D. J. Kim, D. I. Kim, S. K. Lee, S. H. Suh, Y. J. Lee, J. Kim, T. S. Chung and J. E. Lee: Protective effect of agmatine on a reperfusion model after transient cerebral ischemia: Temporal evolution on perfusion MR imaging and histopathologic findings. AJNR Am J Neuroradiol, 27(4), 780-5 (2006)
81. C. C. Wang, C. C. Chio, C. H. Chang, J. R. Kuo and C. P. Chang: Beneficial effect of agmatine on brain apoptosis, astrogliosis, and edema after rat transient cerebral ischemia. BMC Pharmacol, 10, 11 (2010)
82. J. E. Piletz, S. Klenotich, K. S. Lee, Q. L. Zhu, E. Valente, M. A. Collins, V. Jones, S. N. Lee and F. Yangzheng: Putative agmatinase inhibitor for hypoxicischemic new born brain damage. Neurotox Res, 24(2), 176-90 (2013)
83. S. Hong, J. E. Lee, C. Y. Kim and G. J. Seong: Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line. BMC Neurosci, 8, 81 (2007)
84. W. T. Lee, S. Hong, S. H. Yoon, J. H. Kim, K. A. Park, G. J. Seong and J. E. Lee: Neuroprotective effects of agmatine on oxygen-glucose deprived primary-cultured astrocytes and nuclear translocation of nuclear factor-kappa B. Brain Res, 1281, 64-70 (2009)
85. J. H. Kim, Y. W. Lee, K. A. Park, W. T. Lee and J. E. Lee: Agmatine attenuates brain edema through reducing the expression of aquaporin-1 after cerebral ischemia. J Cereb Blood Flow Metab, 30(5), 943-9 (2010)
86. J. H. Kim, Y. W. Lee, Y. M. Park, K. A. Park, S. H. Park, W. T. Lee and J. E. Lee: Agmatine-reduced collagen scar area accompanied with surface righting reflex recovery after complete transection spinal cord injury. Spine (Phila Pa 1976), 36(25), 2130-8 (2011)
87. Y. M. Park, W. T. Lee, K. K. Bokara, S. K. Seo, S. H. Park, J. H. Kim, M. A. Yenari, K. A. Park and J. E. Lee: The multifaceted effects of agmatine on functional recovery after spinal cord injury through Modulations of BMP-2/4/7 expressions in neurons and glial cells. PLoS One, 8(1), e53911 (2013)
88. G. Olmos, N. DeGregorio-Rocasolano, M. Paz Regalado, T. Gasull, M. Assumpcio Boronat, R. Trullas, A. Villarroel, J. Lerma and J. A. Garcia-Sevilla: Protection by imidazol(ine) drugs and agmatine of glutamate-induced neurotoxicity in cultured cerebellar granule cells through blockade of NMDA receptor. Br J Pharmacol, 127(6), 1317-26 (1999)
89. W. P. Wang, A. H. Iyo, J. Miguel-Hidalgo, S. Regunathan and M. Y. Zhu: Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res, 1084, 210-216 (2006)
90. M. Y. Zhu, J. E. Piletz, A. Halaris and S. Regunathan: Effect of agmatine against cell death induced by NMDA and glutamate in neurons and PC12 cells. Cell Mol Neurobiol, 23(4-5), 865-72 (2003)
91. W. P. Wang, A. H. Iyo, J. Miguel-Hidalgo, S. Regunathan and M. Y. Zhu: Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res, 1084(1), 210-6 (2006)
92. Y. Feng, M. H. LeBlanc and S. Regunathan: Agmatine reduces extracellular glutamate during pentylenetetrazole-induced seizures in rat brain: a potential mechanism for the anticonvulsive effects. Neurosci Lett, 390(3), 129-33 (2005)
93. I. Yoko, S. Hong, C. Y. Kim, S. K. Kim and G. J. Seong: Agmatine pretreatment protects retinal ganglion cells (RGC-5 cell line) from oxidative stress in vitro. Biocell, 32(3), 245-250 (2008)
94. D. A. Di Monte: The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol, 2(9), 531-8 (2003)
95. C. A. Ross and W. W. Smith: Gene-environment interactions in Parkinson's disease. Parkinsonism Relat Disord, 13 Suppl 3, S309-15 (2007)
96. M. R. DeLong and T. Wichmann: Circuits and circuit disorders of the basal ganglia. Arch Neurol, 64(1), 20-4 (2007)
97. F. Blandini, R. H. Porter and J. T. Greenamyre: Glutamate and Parkinson's disease. Mol Neurobiol, 12(1), 73-94 (1996)
98. A. Kashani, C. Betancur, B. Giros, E. Hirsch and S. El Mestikawy: Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease. Neurobiol Aging, 28(4), 568-78 (2007)
99. M. C. Rodriguez, J. A. Obeso and C. W. Olanow: Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol, 44(3 Suppl 1), S175-88 (1998)
100. H. Sawada, T. Oeda, S. Kuno, M. Nomoto, K. Yamamoto, M. Yamamoto, K. Hisanaga, T. Kawamura and G. Amantadine Study: Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One, 5(12), e15298 (2010)
101. P. J. Blanchet, S. Konitsiotis and T. N. Chase: Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord, 13(5), 798-802 (1998)
102. D. Aarsland, C. Ballard, Z. Walker, F. Bostrom, G. Alves, K. Kossakowski, I. Leroi, F. Pozo-Rodriguez, L. Minthon and E. Londos: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol, 8(7), 613-8 (2009)
103. M. Emre, M. Tsolaki, U. Bonuccelli, A. Destee, E. Tolosa, A. Kutzelnigg, A. Ceballos-Baumann, S. Zdravkovic, A. Bladstrom, R. Jones and I. Study: Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 9(10), 969-77 (2010)
104. V. G. Kucheryanu and G. N. Kryzhanovskii: Effect of glutamate and antagonists of N-methyl-D-aspartate receptors on experimental parkinsonian syndrome in rats. Bull Exp Biol Med, 130(7), 629-32 (2000)
105. S. Condello, M. Curro, N. Ferlazzo, D. Caccamo, J. Satriano and R. Ientile: Agmatine effects on mitochondrial membrane potential and NF-kappaB activation protect against rotenone-induced cell damage in human neuronal-like SH-SY5Y cells. J Neurochem, 116(1), 67-75 (2011)
106. S. Condello, E. Calabro, D. Caccamo, M. Curro, N. Ferlazzo, J. Satriano, S. Magazu and R. Ientile: Protective effects of agmatine in rotenone-induced damage of human SH-SY5Y neuroblastoma cells: fourier transform infrared spectroscopy analysis in a model of Parkinson's disease. Amino Acids, 42(2-3), 775-81 (2012)
107. K. Leuner, W. E. Muller and A. S. Reichert: From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Mol Neurobiol, 46(1), 186-93 (2012)
108. D. H. Bergin and P. Liu: Agmatine protects against beta-amyloid25-35- induced memory impairments in the rat. Neuroscience, 169(2), 794-811 (2010)
109. P. Liu, Y. Jing, N. D. Collie, S. A. Campbell and H. Zhang: Pre-aggregated Abeta(25-35) alters arginine metabolism in the rat hippocampus and prefrontal cortex. Neuroscience, 193, 269-82 (2011)
110. L. D. Morrison, X. C. Cao and S. J. Kish: Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer's disease. J Neurochem, 71(1), 288-94 (1998)
111. H. G. Bernstein and M. Muller: Increased immunostaining for L-ornithine decarboxylase occurs in neocortical neurons of Alzheimer's disease patients. Neurosci Lett, 186(2-3), 123-6 (1995)
112. R. Seidl, S. Beninati, N. Cairns, N. Singewald, D. Risser, H. Bavan, M. Nemethova and G. Lubec: Polyamines in frontal cortex of patients with Down syndrome and Alzheimer disease. Neurosci Lett, 206(2-3), 193-5 (1996)
113. S. M. Yatin, M. Yatin, T. Aulick, K. B. Ain and D. A. Butterfield: Alzheimer's amyloid beta-peptide associated free radicals increase rat embryonic neuronal polyamine uptake and ornithine decarboxylase activity: protective effect of vitamin E. Neurosci Lett, 263(1), 17-20 (1999)
114. A. I. Maas, N. Stocchetti and R. Bullock: Moderate and severe traumatic brain injury in adults. Lancet Neurol, 7(8), 728-41 (2008)
115. A. D. Gean and N. J. Fischbein: Head trauma. Neuroimaging Clin N Am, 20(4), 527-56 (2010)
116. D. Shlosberg, M. Benifla, D. Kaufer and A. Friedman: Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol, 6(7), 393-403 (2010)
117. K. A. Barbee: Mechanical cell injury. Ann N Y Acad Sci, 1066, 67-84 (2005)
118. C. Werner and K. Engelhard: Pathophysiology of traumatic brain injury. Br J Anaesth, 99(1), 4-9 (2007)
119. M. Schwarzbold, A. Diaz, E. T. Martins, A. Rufino, L. N. Amante, M. E. Thais, J. Quevedo, A. Hohl, M. N. Linhares and R. Walz: Psychiatric disorders and traumatic brain injury. Neuropsychiatr Dis Treat, 4(4), 797-816 (2008)
120. F. Khan, I. J. Baguley and I. D. Cameron: 4: Rehabilitation after traumatic brain injury. Med J Aust, 178(6), 290-5 (2003)
121. S. T. Herman: Epilepsy after brain insult: targeting epileptogenesis. Neurology, 59(9 Suppl 5), S21-6 (2002)
122. K. A. Jellinger, W. Paulus, C. Wrocklage and I. Litvan: Traumatic brain injury as a risk factor for Alzheimer disease. Comparison of two retrospective autopsy cohorts with evaluation of ApoE genotype. BMC Neurol, 1, 3 (2001)
123. B. Roozenbeek, A. I. Maas and D. K. Menon: Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol, 9(4), 231-6 (2013)
124. G. Sengul, E. Takci, U. A. Malcok, A. Akar, F. Erdogan, H. H. Kadioglu and I. H. Aydin: A preliminary histopathological study of the effect of agmatine on diffuse brain injury in rats. J Clin Neurosci, 15(10), 1125-9 (2008)
125. J. R. Kuo, C. J. Lo, C. C. Chio, C. P. Chang and M. T. Lin: Resuscitation from experimental traumatic brain injury by agmatine therapy. Resuscitation, 75(3), 506-14 (2007)
126. J. R. Kuo, C. J. Lo, C. P. Chang, K. C. Lin, M. T. Lin and C. C. Chio: Agmatine-promoted angiogenesis, neurogenesis, and inhibition of gliosis-reduced traumatic brain injury in rats. J Trauma, 71(4), E87-93 (2011)
127. M. L. Schwarzbold, D. Rial, T. De Bem, D. G. Machado, M. P. Cunha, A. A. dos Santos, D. B. dos Santos, C. P. Figueiredo, M. Farina, E. M. Goldfeder, A. L. Rodrigues, R. D. Prediger and R. Walz: Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J Neurotrauma, 27(10), 1883-93 (2010)
128. K. Zahedi, F. Huttinger, R. Morrison, T. Murray-Stewart, R. A. Casero and K. I. Strauss: Polyamine catabolism is enhanced after traumatic brain injury. J Neurotrauma, 27(3), 515-25 (2010)
129. C. J. Murray, A. D. Lopez and D. T. Jamison: The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ, 72(3), 495-509 (1994)
130. G. Alarcon, J. Martinez, S. V. Kerai, M. E. Lacruz, R. Q. Quiroga, R. P. Selway, M. P. Richardson, J. J. Garcia Seoane and A. Valentin: In vivo neuronal firing patterns during human epileptiform discharges replicated by electrical stimulation. Clin Neurophysiol, 123(9), 1736-44 (2012)
131. E. R. Sanabria, H. Su and Y. Yaari: Initiation of network bursts by Ca2+-dependent intrinsic bursting in the rat pilocarpine model of temporal lobe epilepsy. J Physiol, 532(Pt 1), 205-16 (2001)
132. R. Walz, R. M. Castro, T. R. Velasco, C. G. Carlotti, Jr., A. C. Sakamoto, R. R. Brentani and V. R. Martins: Cellular prion protein: implications in seizures and epilepsy. Cell Mol Neurobiol, 22(3), 249-57 (2002)
133. B. W. Connors and M. J. Gutnick: Intrinsic firing patterns of diverse neocortical neurons. Trends Neurosci, 13(3), 99-104 (1990)
134. R. R. Llinas: The intrinsic electrophysiological properties of mammalian neurons: insights into central nervous system function. Science, 242(4886), 1654-64 (1988)
135. D. A. McCormick and D. Contreras: On the cellular and network bases of epileptic seizures. Annu Rev Physiol, 63, 815-46 (2001)
136. L. Yang, S. Afroz, H. B. Michelson, J. H. Goodman, H. A. Valsamis and D. S. Ling: Spontaneous epileptiform activity in rat neocortex after controlled cortical impact injury. J Neurotrauma, 27(8), 1541-8 (2010)
137. H. E. Scharfman: The neurobiology of epilepsy. Curr Neurol Neurosci Rep, 7(4), 348-54 (2007)
138. C. D. Bonan, O. B. Amaral, I. C. Rockenbach, R. Walz, A. M. Battastini, I. Izquierdo and J. J. Sarkis: Altered ATP hydrolysis induced by pentylenetetrazol kindling in rat brain synaptosomes. Neurochem Res, 25(6), 775-9 (2000)
139. C. D. Bonan, R. Walz, G. S. Pereira, P. V. Worm, A. M. Battastini, E. A. Cavalheiro, I. Izquierdo and J. J. Sarkis: Changes in synaptosomal ectonucleotidase activities in two rat models of temporal lobe epilepsy. Epilepsy Res, 39(3), 229-38 (2000)
140. J. Ben, F. Marques Goncalves, P. Alexandre Oliveira, T. Vieira Peres, A. Hohl, R. Bainy Leal, E. Abrao Cavalheiro, R. Daniel Schroder Prediger and R. Walz: Brain MAPKs levels are differentially associated with seizures threshold and severity progression in pentylenetetrazole-kindled mice. CNS Neurosci Ther, 19(9), 726-9 (2013)
141. A. S. Galanopoulou, P. S. Buckmaster, K. J. Staley, S. L. Moshe, E. Perucca, J. Engel, Jr., W. Loscher, J. L. Noebels, A. Pitkanen, J. Stables, H. S. White, T. J. O'Brien, M. Simonato, C. American Epilepsy Society Basic Science and D. The International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug: Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia, 53(3), 571-82 (2012)
142. M. W. Lopes, F. M. Soares, N. de Mello, J. C. Nunes, A. G. Cajado, D. de Brito, F. M. de Cordova, R. M. da Cunha, R. Walz and R. B. Leal: Time-dependent modulation of AMPA receptor phosphorylation and mRNA expression of NMDA receptors and glial glutamate transporters in the rat hippocampus and cerebral cortex in a pilocarpine model of epilepsy. Exp Brain Res, 226(2), 153-63 (2013)
143. M. W. Lopes, F. M. Soares, N. de Mello, J. C. Nunes, F. M. de Cordova, R. Walz and R. B. Leal: Time-dependent modulation of mitogen activated protein kinases and AKT in rat hippocampus and cortex in the pilocarpine model of epilepsy. Neurochem Res, 37(9), 1868-78 (2012)
144. J. E. Piletz, F. Aricioglu, J. T. Cheng, C. A. Fairbanks, V. H. Gilad, B. Haenisch, A. Halaris, S. Hong, J. E. Lee, J. Li, P. Liu, G. J. Molderings, A. L. Rodrigues, J. Satriano, G. J. Seong, G. Wilcox, N. Wu and G. M. Gilad: Agmatine: clinical applications after 100 years in translation. Drug Discov Today, 18(17-18), 880-93 (2013)
145. O. Keynan, Y. Mirovsky, S. Dekel, V. H. Gilad and G. M. Gilad: Safety and Efficacy of Dietary Agmatine Sulfate in Lumbar Disc-associated Radiculopathy. An Open-label, Dose-escalating Study Followed by a Randomized, Double-blind, Placebo-controlled Trial. Pain Med, 11(3), 356-68 (2010)
146. F. Aricioglu, B. Kan, O. Yillar, E. Korcegez and K. Berkman: Effect of agmatine on electrically and chemically induced seizures in mice. Ann N Y Acad Sci, 1009, 141-6 (2003)
147. A. Bahremand, P. Ziai, T. K. Khodadad, B. Payandemehr, R. Rahimian, A. Ghasemi, M. Ghasemi, T. Hedayat and A. R. Dehpour: Agmatine enhances the anticonvulsant effect of lithium chloride on pentylenetetrazole-induced seizures in mice: Involvement of L-arginine/nitric oxide pathway. Epilepsy Behav, 18(3), 186-92 (2010)
148. A. Bahremand, P. Ziai, B. Payandemehr, R. Rahimian, A. Amouzegar, M. Khezrian, L. Montaser-Kouhsari, M. A. Meibodi, A. Ebrahimi, A. Ghasemi, M. Ghasemi and A. R. Dehpour: Additive anticonvulsant effects of agmatine and lithium chloride on pentylenetetrazole-induced clonic seizure in mice: involvement of alpha(2)-adrenoceptor. Eur J Pharmacol, 666(1-3), 93-9 (2011)
149. S. Demehri, H. Homayoun, H. Honar, K. Riazi, K. Vafaie, F. Roushanzamir and A. R. Dehpour: Agmatine exerts anticonvulsant effect in mice: modulation by alpha 2-adrenoceptors and nitric oxide. Neuropharmacology, 45(4), 534-42 (2003)
150. J. J. Luszczki, R. Czernecki, K. Wojtal, K. K. Borowicz and S. J. Czuczwar: Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm, 115(11), 1485-94 (2008)
151. J. J. Luszczki, R. Czernecki, M. Dudra-Jastrzebska, K. K. Borowicz and S. J. Czuczwar: Influence of agmatine on the protective action of numerous antiepileptic drugs against pentetrazole-induced seizures in mice. Pharmacol Rep, 61(2), 252-60 (2009)
152. L. Moezi, H. Shafaroodi, A. Hojati and A. R. Dehpour: The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Behav, 22(2), 200-6 (2011)
153. K. Riazi, H. Honar, H. Homayoun, N. Rashidi, S. Kiani, M. R. Ebrahimkhani, A. R. Noorian, K. Ghaffari, A. Jannati and A. R. Dehpour: The synergistic anticonvulsant effect of agmatine and morphine: possible role of alpha 2-adrenoceptors. Epilepsy Res, 65(1-2), 33-40 (2005)